166 related articles for article (PubMed ID: 2169572)
21. Somatostatin receptor imaging of endocrine gastrointestinal tumors.
Krenning EP; Kwekkeboom DJ; Oei HY; Reubi JC; van Hagen PM; Kooij PP; Reijs AE; Lamberts SW
Schweiz Med Wochenschr; 1992 Apr; 122(17):634-7. PubMed ID: 1350377
[TBL] [Abstract][Full Text] [Related]
22. Intraoperative localization of gut endocrine tumors with radiolabeled somatostatin analogs and a gamma-detecting probe.
Benevento A; Dominioni L; Carcano G; Dionigi R
Semin Surg Oncol; 1998 Dec; 15(4):239-44. PubMed ID: 9829380
[TBL] [Abstract][Full Text] [Related]
23. Somatostatin receptor scintigraphy in pituitary adenomas: a somatostatin receptor density index can predict hormonal and tumoral efficacy of octreotide in vivo.
Duet M; Ajzenberg C; Benelhadj S; Lajeunie E; Lormeau B; Guillausseau PJ; Rohmer V; Vilain D; Mundler O; Warnet A
J Nucl Med; 1999 Aug; 40(8):1252-6. PubMed ID: 10450674
[TBL] [Abstract][Full Text] [Related]
24. [A new diagnostic method: somatostatin receptor scintigraphy of neuroendocrine tumors].
Westlin JE; Janson ET; Ahlström H; Ohrvall U; Arnberg H; Nilsson S; Akerström G; Oberg K
Lakartidningen; 1992 Dec; 89(50):4377-9. PubMed ID: 1469974
[No Abstract] [Full Text] [Related]
25. Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide.
Hofland LJ; van Koetsveld PM; Waaijers M; Zuyderwijk J; Breeman WA; Lamberts SW
Endocrinology; 1995 Sep; 136(9):3698-706. PubMed ID: 7649075
[TBL] [Abstract][Full Text] [Related]
26. Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity, and in vivo application in animals.
Bakker WH; Krenning EP; Breeman WA; Koper JW; Kooij PP; Reubi JC; Klijn JG; Visser TJ; Docter R; Lamberts SW
J Nucl Med; 1990 Sep; 31(9):1501-9. PubMed ID: 1975618
[TBL] [Abstract][Full Text] [Related]
27. The visualization of gastroenteropancreatic endocrine tumors.
Lamberts SW; Chayvialle JA; Krenning EP
Digestion; 1993; 54 Suppl 1():92-7. PubMed ID: 8395433
[TBL] [Abstract][Full Text] [Related]
28. Comparison of labeled MIBG and somatostatin analogs in imaging neuroendocrine tumors.
Lastoria S; Maurea S; Vergara E; Acampa W; Varrella P; Klain M; Muto P; Bernardy JD; Salvatore M
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):145-9. PubMed ID: 9002775
[TBL] [Abstract][Full Text] [Related]
29. Neuroendocrine tumors and somatostatin: imaging techniques.
de Herder WW; Kwekkeboom DJ; Valkema R; Feelders RA; van Aken MO; Lamberts SW; van der Lely AJ; Krenning EP
J Endocrinol Invest; 2005; 28(11 Suppl International):132-6. PubMed ID: 16625862
[TBL] [Abstract][Full Text] [Related]
30. The visualization of gastroenteropancreatic endocrine tumors.
Lamberts SW; Chayvialle JA; Krenning EP
Metabolism; 1992 Sep; 41(9 Suppl 2):111-5. PubMed ID: 1355584
[TBL] [Abstract][Full Text] [Related]
31. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors.
Virgolini I; Raderer M; Kurtaran A; Angelberger P; Banyai S; Yang Q; Li S; Banyai M; Pidlich J; Niederle B; Scheithauer W; Valent P
N Engl J Med; 1994 Oct; 331(17):1116-21. PubMed ID: 7935635
[TBL] [Abstract][Full Text] [Related]
32. A scintigraphic comparison of iodine-123-metaiodobenzylguanidine and an iodine-labeled somatostatin analog (Tyr-3-octreotide) in metastatic carcinoid tumors.
Bomanji J; Mather S; Moyes J; Ellison D; Grossman A; Britton KE; Besser GM
J Nucl Med; 1992 Jun; 33(6):1121-4. PubMed ID: 1597726
[TBL] [Abstract][Full Text] [Related]
33. Receptor scintigraphy with 111In-pentetreotide for endocrine gastroenteropancreatic tumors.
Joseph K; Stapp J; Reinecke J; Skamel HJ; Höffken H; Neuhaus C; Lenze H; Trautmann ME; Arnold R
Horm Metab Res Suppl; 1993; 27():28-35. PubMed ID: 8330869
[TBL] [Abstract][Full Text] [Related]
34. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
Boni G; Ferdeghini M; Bellina CR; Matteucci F; Castro Lopez E; Parenti G; Canapicchi R; Bianchi R
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
[TBL] [Abstract][Full Text] [Related]
35. Use of an isotopic somatostatin receptor probe to image gut endocrine tumors.
Modlin IM; Cornelius E; Lawton GP
Arch Surg; 1995 Apr; 130(4):367-73; discussion 373-4. PubMed ID: 7710334
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic reliability of somatostatin receptor scintigraphy during continuous treatment with different somatostatin analogs.
Dörr U; Wurm K; Höring E; Guzman G; Räth U; Bihl H
Horm Metab Res Suppl; 1993; 27():36-43. PubMed ID: 8330870
[TBL] [Abstract][Full Text] [Related]
37. Structure and function of somatostatin receptors in growth hormone control.
Shimon I; Melmed S
J Endocrinol; 1997 Oct; 155 Suppl 1():S3-6; discussion S7-8. PubMed ID: 9389989
[TBL] [Abstract][Full Text] [Related]
38. 111In-octreotide scintigraphy in oncology.
Krenning EP; Kwekkeboom DJ; Reubi JC; Van Hagen PM; van Eijck CH; Oei HY; Lamberts SW
Metabolism; 1992 Sep; 41(9 Suppl 2):83-6. PubMed ID: 1355591
[TBL] [Abstract][Full Text] [Related]
39. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas.
Reubi JC; Kvols LK; Waser B; Nagorney DM; Heitz PU; Charboneau JW; Reading CC; Moertel C
Cancer Res; 1990 Sep; 50(18):5969-77. PubMed ID: 2168286
[TBL] [Abstract][Full Text] [Related]
40. Somatostatin analogs in the treatment of acromegaly.
Lamberts SW; Reubi JC; Krenning EP
Endocrinol Metab Clin North Am; 1992 Sep; 21(3):737-52. PubMed ID: 1355729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]